Theriva Biologics Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure


CEO

Steve Shallcross (61 yo)

4.17yrs

Tenure

US$1,121,124

Compensation

Mr. Steven A. Shallcross, also known as Steve, CPA, was an Independent Director of Forza X1, Inc., since December 2021. He served as Independent Director at Twin Vee Powercats Co. since April 8, 2021 until...


CEO Compensation Analysis

How has Steve Shallcross's remuneration changed compared to Theriva Biologics's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$1mUS$585k

-US$23m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$1mUS$565k

-US$13m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$1mUS$550k

-US$16m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$26m

Mar 31 2019n/an/a

-US$27m

Dec 31 2018US$963kUS$489k

-US$25m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$22m

Dec 31 2017US$799kUS$347k

-US$22m

Sep 30 2017n/an/a

-US$27m

Jun 30 2017n/an/a

-US$18m

Mar 31 2017n/an/a

-US$19m

Dec 31 2016US$921kUS$315k

-US$27m

Compensation vs Market: Steve's total compensation ($USD1.12M) is above average for companies of similar size in the US market ($USD729.23K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Steven Shallcross
CEO, CFO7.67yrsUS$1.12m1.06%
$ 148.8k
Frank Tufaro
Chief Operating Officer0.92yrno data0.53%
$ 75.0k
Vincent Perrone
Director of Corporate Communicationno datano datano data
Vince Wacher
Head of Product and Corporate Developmentno datano datano data
Michael Kaleko
Senior Vice President of Research & Development10.33yrsno datano data
Lara Guzman
Senior Director of Project Operationsno datano datano data

7.7yrs

Average Tenure

Experienced Management: TOVX's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Shallcross
CEO, CFO4.17yrsUS$1.12m1.06%
$ 148.8k
John Monahan
Independent Director2.25yrsUS$110.62kno data
Jeffrey Kraws
Independent Non-Executive Chairman17.08yrsUS$220.62k0.0043%
$ 607.6
Mark Blumenkranz
Member of Scientific Advisory Board0.75yrno datano data
Jeffrey Wolf
Independent Director17.08yrsUS$118.12kno data
Ramon Alemany
Chairman of Scientific Advisory Board0.75yrno datano data
Curtis Donskey
Member of C Difficile Clinical Advisory Board8.67yrsno datano data
Thomas Louie
Member of C Difficile Clinical Advisory Board8.67yrsno datano data
Ciarán Kelly
Member of C Difficile Clinical Advisory Board8.67yrsno datano data
Mark Wilcox
Chairman of C Difficile Clinical Advisory Board8.67yrsno datano data
Richard Hodin
Member of Intestinal Alkaline Phosphatase Clinical Advisory Board2.67yrsno datano data
Ennio Chiocca
Member of Scientific Advisory Board0.75yrno datano data

6.4yrs

Average Tenure

61yo

Average Age

Experienced Board: TOVX's board of directors are considered experienced (6.4 years average tenure).